We included 44 593 patients from 14 randomized placebo-controlled clinical trials [10,11,32–40,52,56,58] of five SGLT-2 inhibitors (empagliflozin [n = 4], canagliflozin [n = 3], dapagliflozin [n = 4], ertugliflozin [n = 1], and sotagliflozin [n = 2]) in patients with CKD. This evidence concerns the gene SLC5A2 and chronic kidney disease.